Synapse - Nursing

Results (100)

Evaluation of immune-related adverse events (irAE): Utilizing the patient-reported outcomes of the common terminology criteria for adverse events (PRO-CTCAE) in a phase II study of ipilimumab (ipi) in men with castration-sensitive prostate cancer (CSPC)

Meeting Abstract

Vargas Pivato de Almeida, D.; Anderson, J.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Abida, W.; Dayan, E. S.; Curley, T.; Arauz, G.; Baser, R. E.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

c15-160: Enzalutamide (ENZA) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC): A phase 1b Prostate Cancer Clinical Trials Consortium study

Meeting Abstract

Rathkopf, D. E.; Autio, K. A.; Antonarakis, E. S.; Cheng, H. H.; Arauz, G.; Slack, A.; Hullings, M.; Scher, H. I.; Feng, F. Y.; Knudsen, K. E.
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer

Journal Article

Graham, L.; Banda, K.; Torres, A.; Carver, B. S.; Chen, Y.; Pisano, K.; Shelkey, G.; Curley, T.; Scher, H. I.; Lotan, T. L.; more...
Investigational New Drugs (2018)

Fulltext@MSK | Save

Circulating tumor cells (CTCs) N-terminal androgen receptor expression to identify patients (pts) with castrate resistant prostate cancer (CRPC) who are more sensitive to chemotherapy

Meeting Abstract

Slovin, S. F.; Knudsen, K. E.; Halabi, S.; Carbone, E.; Fernandez, C.; Chen, Y.; Autio, K. A.; Rathkopf, D. E.; Kampel, L.; Morris, M. J.; more...
Journal of Clinical Oncology (2017)

Fulltext@MSK | Save

Baseline CTC subtype to predict outcomes on mCRPC patients (pts) receiving enzalutamide (E) compared to abiraterone (A)

Meeting Abstract

Scher, H. I.; Jendrisak, A.; Schreiber, N. A.; McLaughlin, B.; Graf, R. P.; Rodriguez, A.; Fleisher, M.; Lee, J.; Kelvin, J.; Wang, Y.; more...
Journal of Clinical Oncology (2017)

Fulltext@MSK | Save

Changes in CTC burden and prevalence of specific CTC subtypes in mCRPC patients (pts) receiving alpharadin (Ra-223) as single agent or in combination with other therapuetics (Tx)

Meeting Abstract

Dittamore, R. V.; Jendrisak, A.; Schreiber, N. A.; McLaughlin, B.; Graf, R.; Rodriguez, A.; Fleisher, M.; Lee, J.; Kelvin, J.; Wang, Y.; more...
Journal of Clinical Oncology (2017)

Fulltext@MSK | Save

Overall survival results of a randomized trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment

Meeting Abstract

Basch, E. M.; Deal, A. M.; Dueck, A. C.; Bennett, A. V.; Atkinson, T. M.; Scher, H. I.; Kris, M. G.; Hudis, C. A.; Sabbatini, P.; Dulko, D.; more...
Journal of Clinical Oncology (2017)

Fulltext@MSK | Save

Exploring the role of RB and AR in a phase II randomized multicenter trial of abiraterone acetate with or without cabazitaxel in metastatic castration resistant prostate cancer (mCRPC)

Meeting Abstract

Slovin, S. F.; Knudsen, K. E.; Carbone, E.; Showunmi, A.; Hullings, M.; Morris, M. J.; Autio, K. A.; Kampel, L. J.; Molina, A. M.; Chen, Y.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

AR-V7 and CTC heterogeneity biomarkers additively to predict patient (pt) outcomes with taxanes relative to approved AR targeted therapy

Meeting Abstract

Scher, H. I.; Graf, R.; Schreiber, N. A.; McLaughlin, B.; Lu, D.; Louw, J.; Jendrisak, A.; Greene, S.; Rodriguez, A.; Dugan, L.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

A Phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Rathkopf, D. E.; Slovin, S. F.; Autio, K. A.; Delacruz, A.; Shelkey, G.; Pisano, K.; Hullings, M.; DeNunzio, M.; Morris, M. J.; Scher, H. I.
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save